60 Degrees (SXTP) news
Recent news
60 Degrees Pharmaceuticals Q2 EPS USD -0.9
AInvest Wire · Aug 14, 202660 Degrees Pharmaceuticals Q2 operating expenses USD 2.33 million
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) reported decrease from $4.22 million recorded in the same period of 2024. The reduction in expenses was primarily attributed to absence of one-off charges that had impacted the 2024 quarter. Despite the decline in operating expenses, the…
AInvest Wire · Aug 14, 202660 Degrees Pharmaceuticals, Inc. announces private placement priced at-the-market under Nasdaq rules
60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has announced a private placement offering priced at-the-market under Nasdaq rules, with the company seeking to raise up to $565,000 through the sale of common stock. The offering is conducted under an existing at-the-market (ATM) Sales Agreement with…
AInvest Wire · Jul 30, 202660 Degrees Pharmaceuticals - may submit NDA for tafenoquine to FDA before end of Q1 2028 - SEC filing
AInvest Wire · Jun 3, 202660 Degrees Pharmaceuticals climbs 7% premarket after getting a Hold from H.C. Wainwright
60 Degrees Pharmaceuticals climbs 7% premarket after getting a Hold from H.C. Wainwright 60 Degrees Pharmaceuticals, Inc. (SXTP) experienced a significant rise in its pre-market trading after receiving a "Hold" rating from H.C. Wainwright, a renowned financial services firm. The stock climbed by 7%…
AInvest Wire · Jan 23, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.